Close
Country websites:

UltraLow GDP

UltraLow GDP image

Choose the right fluid

  • PD fluids with lowest GDP levels – only from Fresenius Medical Care1
  • Less hospitalization costs2
  • UltraLow GDP therapy pays off from day one
  • For CAPD and APD therapy

 

 

 

  • Benefits
  • Studies
  • Product
  • Prescribing Information

Minimize GDP-related complications

PD fluids with lowest GDP levels – only from Fresenius Medical Care1

GDP concentrations in PD fluids vary significantly.
GPD concentrations in PD fluids vary significantly.

Less hospitalization costs2

UltraLow GDP therapy pays off from day one

For CAPD and APD therapy

balANZ study

The balANZ study: clear advantages for your patients5,6,10

balANZ: main publication

“Effects of Biocompatible versus Standard Fluid on Peritoneal Dialysis Outcomes”10

Key results from this publication
Patients on balance showed:
Delayed onset of anuria7% vs 20% anuric patients (p = 0.009)
Reduced incidence of peritonitis 30% vs 49% of patients (p = 0.01)
Read the article

 

 

 

balANZ: membrane

“The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial”6

Key results from this publication
Patients on balance showed:
More stable peritoneal membrane transport by D/P creatinine (p < 0.001)
Read the article

 

 

 

balANZ: infection

“The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial”5

Key results discussed in this publication
Patients on balance showed:
Shorter medium duration of peritonitis-associated hospitalization 6 vs 11 days (p = 0.05)
Milder peritonitis severity 37% vs 10% of episodes (p = 0.001)
Reduced incidence of peritonitis 30% vs 49% of patients (p = 0.01)
Read the article

GDPs analysis

“A new neutral-pH low-GDP peritoneal dialysis fluid”1

Key results discussed in this publication

GDP concentrations in balance are considerably lower than in other biocompatible PD fluids.1
In particular, balance contains only minor amounts of the most bio-reactive GDPs 3,4-Dideoxyglucosone-3-ene (3,4-DGE) and 3-Deoxyglucosone(3-DG).1
Read the article

PD fluids with lowest GDP levels – only from Fresenius Medical Care1

PD Fluids
balance – UltraLow GDP fluid

For CAPD and APD therapy

balance

Abbreviated Prescribing Information for balance

PDF , 280.0 KB

Abbreviated Prescribing Information for balance

PDF , 280.0 KB

Abbreviated Prescribing Information for balance

PDF , 280.0 KB

1 Himmele R, Jensen L, Fenn D, Ho C, Sawin D, Diaz–Buxo J. A new neutral-pH low-GDP peritoneal dialysis fluid. Peritoneal Dialysis International 2012;32(4):444-52.

2 Johnson D, EuroPD 2013.

3 Schwenger V. GDP and AGE receptors: mechanisms of peritoneal damage. Contributions to Nephrology 2006;150:77-83.

4 Cho Y, Johnson D, Badve S, Craig J, Strippoli G, Wiggins K. The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney International 2013 May 22. [Epub ahead of print]

5 Johnson D, Brown F, Clarke M, Boudville N, Elias T, Foo M, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan S, Voss D; balANZ Trial Investigators. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balanz trial. Peritoneal Dialysis International 2012;32(5):497-506.

6 Johnson D, Brown F, Clarke M, Boudville N, Elias T, Foo M, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan S, Voss D; balANZ Trial Investigators. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. Nephrology Dialysis Transplantation 2012;27(12):4445-53.

7 Williams J, Topley N, Craig K, Mackenzie R, Pischetsrieder M, Lage C, Passlick-Deetjen J; Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney International 2004;66(1):408-18.

8 Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert C, Ahlmén J, Larsson R, Ingmann B, Simonsen O, van Hamersvelt H, Johansson A, Hylander B, Mayr M, Nilsson P, Andersson P, De los Rios T. Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Peritoneal Dialysis International 2009;29(6):630-633.

9 Montenegro J, Saracho R, Gallardo I, Martínez I, Munoz R and Quintanilla N. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrology Dialysis Transplantation 2007;22(6):1703-1708.

10 Johnson D, Brown F, Clarke M, Boudville N, Elias T, Foo M, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan S, Voss D; balANZ Trial Investigators. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. Journal of the American Society of Nephrology 2012;23(6):1097-107.

11 Blake P. Balance about balANZ. Peritoneal Dialysis International 2012;32(5):493-6.